Literature DB >> 15264790

Evolution of the lateral extracavitary approach to the spine.

Jason Lifshutz1, Zvi Lidar, Dennis Maiman.   

Abstract

The development of alternative approaches to spine disorders marked an evolutionary change in the methods by which surgeons address diseases that affect the ventral portion of the spine. From the advent of spinal surgery until quite recently, physicians used posterior approaches almost exclusively for the treatment of all pathological processes. Surgeons subsequently became frustrated and disenchanted with outcomes of patients with anterior vertebral body disease when these procedures were applied. This sentiment is best reflected in the surgical thought related to Pott disease. In this paper, the authors chart the development of an influential approach to the spine that is designed to address these issues: the lateral extracavitary approach. They trace its origins to early precursor procedures and follow its use in current practice for the treatment of a variety of spinal disorders. They also examine its applications, role, and continued importance in the age of minimally invasive surgery.

Entities:  

Mesh:

Year:  2004        PMID: 15264790

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  2 in total

1.  Thoracic corpectomy for neoplastic vertebral bodies using a navigated lateral extracavitary approach-a single-center consecutive case series: technique and analysis.

Authors:  Sebastian Hartmann; Christoph Wipplinger; Anja Tschugg; Pujan Kavakebi; Alexander Örley; Pierre Pascal Girod; Claudius Thomé
Journal:  Neurosurg Rev       Date:  2017-08-17       Impact factor: 3.042

2.  Comparison of polymethylmethacrylate versus expandable cage in anterior vertebral column reconstruction after posterior extracavitary corpectomy in lumbar and thoraco-lumbar metastatic spine tumors.

Authors:  Mohammed Eleraky; Ioannis Papanastassiou; Nam D Tran; Elias Dakwar; Frank D Vrionis
Journal:  Eur Spine J       Date:  2011-03-10       Impact factor: 3.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.